Dr. Balraj Singh from the Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, describes a recent research paper he co-authored that was published by Oncotarget, entitled, "Inhibition of resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine."
DOI - https://doi.org/10.18632/oncotarget.27922
Full text - https://www.oncotarget.com/article/27922/text/
Correspondence to - Anthony Lucci - [email protected], and Balraj Singh - [email protected]
Keywords - resistant TNBC, minimal residual disease, intratumor heterogeneity, breast cancer relapse, metastasis prevention
Copyright © 2023 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC